Uniform Titchmarsh divisor problems

Asymptotic formulae for Titchmarsh-type divisor sums are obtained with strong error terms that are uniform in the shift parameter. This applies to more general arithmetic functions such as sums of two squares, improving the error term in the representation of the number as a sum of a prime and two squares, and to Fourier coefficients of cusp forms, generalizing a result of Pitt

New records, detailed distribution and abundance of rove-beetles (Insecta, Coleoptera, Staphylinidae) collected between 1990 and 2015 in Azores (Portugal) with an updated checklist

Background: The dataset we present consists of an inventory compiling all records and knowledge about Staphylinidae (Insecta, Coleoptera) in the Azores and is part of a long-term monitoring performed between 1990 and 2015 in different habitat types of eight islands of the Azores Archipelago. Most samples come from the BALA project (Biodiversity of Arthropods from the Laurisilva of Azores) that sampled native forests in the Azores. Additional sampled habitats include exotic forests, intensive and semi-natural pasturelands, orchards, caves and lava flows. Most of the records (about 96.7%) were collected in standardised sampling campaigns, which included pitfall traps and beating transect protocols. Non-standardised records are based on hand-collecting and sifting, as well as cave, colour and malaise traps. New information: We provide a long-term inventory of Staphylinidae (Insecta, Coleoptera) collected in the course of several standardised sampling campaigns and recorded with non-standardised methods. We collected a total of 10744 specimens belonging to 69 identified species of Staphylinidae, which represents 51% of the species known from the Azores Archipelago. Four endemic species were sampled, representing 40% of the known Azorean endemic species. From this dataset, seven species are new for the Azores: Aleochara funebris Wollaston, 1864; Amischa forcipata Mulsant & Rey, 1873; Bledius unicornis (Germar, 1825); Carpelimus troglodytes (Erichson, 1840); Cypha seminulum (Erichson, 1839); Paraphloeostiba gayndahensis (MacLeay, 1871); Tachyporus caucasicus Kolenati, 1846. We also registered a total of 66 new island records for eight Azorean islands. This contribution continues a series of publications on the distribution and abundance of Azorean arthropods. We also provide an updated list of Azorean rove-beetles (Staphylinidae) that now includes 136 species, ten of them considered Azorean endemics.Species collecting was possible, based on the funding from the following projects: "Reservas Florestais dos Açores: Cartografia e Inventariação dos Artrópodes Endémicos dos Açores" (BALA) (Direccao Regional dos Recursos Florestais, project 17.01-080203) (1999-2003) ; "Agriculture, habitat fragmentation, indicator species and conservation of endemic fauna and flora in the Azores - the 2010 Target" (Direccao Regional da Ciência e Tecnologia, DRCT-Postdoc M112/F/014/2007) (2007-2009) ; "Predicting extinctions on islands: a multi-scale assessment" (Fundação para a Ciência e Tecnologia-FCT-PTDC/BIA-BEC/100182/2008) (2010-2013) ; "Understanding biodiversity dynamics in tropical and subtropical islands as an aid to science based conservation action" (ISLANDBIODIV) (Fundação para a Ciência e Tecnologia, FCT/NETBIOME/0003) . The database management was funded by FEDER (85%) and by Azorean Public funds (15%) through Operational Programme Azores 2020, under the project AZORESBIOPORTAL -PORBIOTA (ACORES-01-0145-FEDER-000072).info:eu-repo/semantics/publishedVersio

Updated Checklist of Arthropods from Azores (Portugal)

The data we present consists in an updated checklist of the Azorean arthropods. The checklist compile known records based on published literature, unpublished data, and new records at archipelago and island levels. This publication represents the most recent information about distribution of introduced, native and endemic arthropods in the Azores archipelago. Currently the total number of terrestrial arthropod taxa (species and subspecies) in the Azores is estimated of about 2417 belonging to 14 classes, 53 orders, 438 families, 1554 genera and 2397 species and 149 individual subspecies. The most diverse orders of Azorean arthropods are: Coleoptera (585 taxa), Diptera (422 taxa), Hemiptera (338 taxa), Hymenoptera (162 taxa), Lepidoptera (159 taxa) and Araneae (132 taxa). A total of 275 endemic taxa are currently known (231 species and 44 subspecies), belonging to 8 classes and 22 orders. São Miguel, Terceira and Pico are the islands with higher number of endemic species and subspecies. Compared to the other nearest Macaronesian archipelagos (Madeira and Canaries), the Azorean arthropod fauna is characterized by a lower percentage of endemism and a high proportion of exotic introduced species.FUNDING: This work was financed by two main projects: FEDER - AZORESBIOPORTAL –PORBIOTA (ACORES-01-0145-FEDER-000072) and Portal da Biodiversidade dos Açores (2022-2023) - PO Azores Project - M1.1.A/INFRAEST CIENT/001/2022. Open access was funded by the project FCT-UIDB/00329/2020-2024 (Thematic Line 1 – integrated ecological assessment of environmental change on biodiversity).info:eu-repo/semantics/publishedVersio

An Updated Checklist of Azorean Arthropods (Arthropoda)

Peer reviewe

Humoral and Cellular CMV Responses in Healthy Donors; Identification of a Frequent Population of CMV-Specific, CD4+ T Cells in Seronegative Donors

CMV status is an important risk factor in immune compromised patients. In hematopoeitic cell transplantations (HCT), both donor and recipient are tested routinely for CMV status by serological assays; however, one might argue that it might also be of relevance to examine CMV status by cellular (i.e., T lymphocyte) assays. Here, we have analyzed the CMV status of 100 healthy blood bank donors using both serology and cellular assays. About half (56%) were found to be CMV seropositive, and they all mounted strong CD8+ and/or moderate CD4+ T cell responses ex vivo against the immunodominant CMV protein, pp65. Of the 44 seronegative donors, only five (11%) mounted ex vivo T cell responses; surprisingly, 33 (75%) mounted strong CD4+ T cell responses after a brief in vitro peptide stimulation culture. This may have significant implications for the analysis and selection of HCT donors

Targeted prevention in primary care aimed at lifestyle-related diseases:a study protocol for a non-randomised pilot study

Background: The consequences of lifestyle-related disease represent a major burden for the individual as well as for society at large. Individual preventive health checks to the general population have been suggested as a mean to reduce the burden of lifestyle-related diseases, though with mixed evidence on effectiveness. Several systematic reviews, on the other hand, suggest that health checks targeting people at high risk of chronic lifestyle-related diseases may be more effective. The evidence is however very limited. To effectively target people at high risk of lifestyle-related disease, there is a substantial need to advance and implement evidence-based health strategies and interventions that facilitate the identification and management of people at high risk. This paper reports on a non-randomized pilot study carried out to test the acceptability, feasibility and short-term effects of a healthcare intervention in primary care designed to systematically identify persons at risk of developing lifestyle-related disease or who engage in health-risk behavior, and provide targeted and coherent preventive services to these individuals. Methods: The intervention took place over a three-month period from September 2016 to December 2016. Taking a two-pronged approach, the design included both a joint and a targeted intervention. The former was directed at the entire population, while the latter specifically focused on patients at high risk of a lifestyle-related disease and/or who engage in health-risk behavior. The intervention was facilitated by a digital support system. The evaluation of the pilot will comprise both quantitative and qualitative research methods. All outcome measures are based on validated instruments and aim to provide results pertaining to intervention acceptability, feasibility, and short-term effects. Discussion: This pilot study will provide a solid empirical base from which to plan and implement a full-scale randomized study with the central aim of determining the efficacy of a preventive health intervention. Trial registration: Registered at Clinical Trial Gov (Unique Protocol ID: TOFpilot2016). Registered 29 April 2016. The study adheres to the SPIRIT guidelines

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

BACKGROUND: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. METHODS: We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794. FINDINGS: Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of -0·22 mm per year (-0·41 to -0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means -0·10 per year, 95% CI -0·19 to -0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events. INTERPRETATION: Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications